Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 2, 2014, Pages 227-233

  Yoon, Soomin ^a   Kim, Yun Hee ^b   Kang, Se Hun ^b   Kim, Seok Ki ^b   Lee, Hwa Kyoung ^a   Kim, Hyori ^a   Chung, Junho ^a   Kim, In Hoo ^b  

^a Seoul National University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

Bispecific antibody; Cotinine; Hapten; Human epidermal growth factor receptor 2 (Her2); In vivo imaging; Pre targeting

Indexed keywords

ANIMALS; ANTIBODIES, BISPECIFIC; BREAST NEOPLASMS; COTININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HETEROGRAFTS; HISTIDINE; HUMANS; IODINE RADIOISOTOPES; MICE; MICE, INBRED BALB C; MICE, NUDE; RADIOIMMUNOASSAY; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; TUMOR CELLS, CULTURED;

EID: 84895077137     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1548-4     Document Type: Article

References (33)

1. Anderson K, Lai ZH, McDonald OB, Stuart JD, Nartey EN et al (2009) Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time. Biochem J 420:259-265
2. Baxter AB, Melnikoff S, Stites DP, Brasch RC (1991) Immunogenicity of gadolinium-based contrast agents for magnetic-resonance-imaging - induction and characterization of antibodies in animals. Invest Radiol 26:1035-1040
3. Behr TM, Gotthardt M, Becker W, Behe M (2002) Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy - a review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Gottingen/Marburg experience. Nuklearmedizin-Nucl Med 41:71-79
4. Boerman OC, van Schaijk FG, Oyen WJG, Corstens FHM (2003) Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 44:400-411
5. Bowman Edward R, Herbert McKennis J (1962) Studies on the metabolism of (-)-cotinine in the human. J Pharmacol Exp Ther 135:306
6. Carter P, Presta L, Gorman CM, Ridgway JBB, Henner D et al (1992) Humanization of an Anti-P185her2 antibody for human cancer-therapy. Proc Natl Acad Sci USA 89:4285-4289
7. Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W et al (2002) Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther 1:553-563
8. Chang CH, Rossi EA, Goldenberg DM (2007) The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res 13:5586s-5591s
9. Chatal JF, Davodeau F, Cherel M, Barbet J (2009) Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors. J Cancer Res Ther 5:36-40
10. Colombo P, Siccardi AG, Paganelli G, Magnani P, Songini C et al (1996) Three-step immunoscintigraphy with anti-chromogranin a monoclonal antibody in tumours of the pituitary region. Eur J Endocrinol 135:216-221
11. Fritz T, Unger E, Wilsonsanders S, Ahkong QF, Tilcock C (1991) Detailed toxicity studies of liposomal gadolinium-DTPA. Invest Radiol 26:960-968
12. Gautherot E, Le Doussal JM, Bouhou J, Manetti C, Martin M et al (1998) Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. J Nucl Med 39:1937-1943
13. Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH (2008) Multifunctional antibodies by the dock-and-lock method for improved cancer Imaging and therapy by pretargeting. J Nucl Med 49:158-163
14. Jakubowski H (2002) Understanding biochemical dissociation constants: a temporal perspective. J Chem Educ 79:968-971
15. Karacay H, Brard PY, Sharkey RM, Chang CH, Rossi EA et al (2005) Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res 11:7879-7885
16. Kim I, Huestis MA (2006) A validated method for the determination of nicotine, cotinine, trans-3′-hydroxycotinine, and norcotinine in human plasma using solid-phase extraction and liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. J Mass Spectrom 41:815-821
17. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L et al (2000) Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 6:406-414
18. Kosmas C, Snook D, Gooden CS, Courtenayluck NS, Mccall MJ et al (1992) Development of humoral immune-responses against a macrocyclic chelating agent (Dota) in cancer-patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res 52:904-911
19. Kosmas C, Maraveyas A, Gooden CS, Snook D, Epenetos AA (1995) Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal-antibody immunoconjugates for ovarian-cancer therapy. J Nucl Med 36:746-753
20. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M et al (2006) Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 66:8266-8273
21. Meyer DCC, Port M, Barbotin V, Bonnemain B (2010) Process for preparing a pharmaceutical formulation of contrast agents. EP2242515 A2
22. Milenic DE, Brady ED, Brechbiel MW (2004) Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 3:488-498
23. Moran VE (2012) Cotinine: beyond the expected, more than a biomarker of tobacco consumption. Frontiers Pharmacol 3:1-9
24. Olafsen T, Tan GJ, Cheung CW, Yazaki PJ, Park JM et al (2004) Characterization of engineered anti-pI85(HER-2) (scFv-C(H)3)(2) antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 17:315-323
25. Orcutt KD, Nasr KA, Whitehead DG, Frangioni JV, Wittrup KD (2011) Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy. Mol Imag Biol 13:215-221
26. Paganelli G, Riva P, Deleide G, Clivio A, Chiolerio F et al. (1988) Invivo labeling of biotinylated monoclonal-antibodies by radioactive avidin - a strategy to increase tumor radiolocalization. Int J Cancer 2:121-125
27. Park S, Lee DH, Park JG, Lee YT, Chung J (2010) A sensitive enzyme immunoassay for measuring cotinine in passive smokers. Clin Chim Acta 411:1238-1242
28. Park S, Hwang D, Chung J (2012) Cotinine-conjugated aptamer/anti-cotinine antibody complexes as a novel affinity unit for use in biological assays. Exp Mol Med 44:554-561
29. Riah O, Dousset JC, Courriere P, Stigliani JL, Baziard-Mouysset G et al (1999) Evidence that nicotine acetylcholine receptors are not the main targets of cotinine toxicity. Toxicol Lett 109:21-29
30. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM et al (2006) Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA 103:6841-6846
31. Sharkey RM, Karacay H, Chang CH, McBride WJ, Horak ID et al (2005) Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia 19:1064-1069
32. Sharkey RM, Rossi EA, McBride WJ, Chang CH, Goldenberg DM (2010) Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med 40:190-203
33. Watanabe N, Goodwin DA, Meares CF, Mctigue M, Chaovapong W et al (1994) Immunogenicity in rabbits and mice of an antibody-chelate conjugate - comparison of (S) and (R) macrocyclic enantiomers and an acyclic chelating agent. Cancer Res 54:1049-1054